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Liver and lung metastases are the predominant cause of colorectal cancer (CRC)-related mortality. Recent research has indicated that
CXCR3/chemokines interactions that orchestrate haematopoetic cell movement are implicated in the metastatic process of
malignant tumours, including that of CRC cells to lymph nodes. To date, however, the contribution of CXCR3 to liver and lung
metastasis in CRC has not been addressed. To determine whether CXCR3 receptors regulate malignancy-related properties of CRC
cells, we have used CXCR3-expressing CRC cell lines of human (HT29 cells) and murine (C26 cells) origins that enable the
development of liver and lung metastases when injected into immunodeficient and immunocompetent mice, respectively, and
assessed the effect of CXCR3 blockade using AMG487, a small molecular weight antagonist. In vitro, activation of CXCR3 on human
and mouse CRC cells by its cognate ligands induced migratory and growth responses, both activities being abrogated by AMG487. In
vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited the implantation and the
growth of human and mouse CRC cells within lung without affecting that in the liver. In addition, we measured increased levels of
CXCR3 and ligands expression within lung nodules compared with liver tumours. Altogether, our findings indicate that activation of
CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that
inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models.
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Similar to the majority of solid malignant tumours, colorectal
carcinoma (CRC) develops metastases that are the major source of
morbidity and mortality. More than one-half of all patients
develop metastases, especially in the liver (50% of patients) and
lung (15% of patients) (Chambers et al, 2002). Owing to the
inability to eradicate the metastases with the currently available
therapies, new strategies are needed to prevent and eradicate
metastases in the target organs and to improve the survival rate of
patients. There is mounting evidence that the organ-specific
metastasis is governed, in part, by interactions between chemokine
receptors expressed on cancer cells and the corresponding
chemokines secreted within the target organs (Balkwill, 2004). Of
particular interest, the CXCR4/CXCL12 interaction was the first
ligand–receptor pair identified to play a critical role in determin-
ing the metastatic destination of breast cancer cells to the lungs
(Mu ¨ller et al, 2001) and has, since then, been involved in the
metastatic spread of many other cancer cells to various target
organs (Payne and Cornelius, 2002; Taichman et al, 2002; Smith
et al, 2004; Perissinotto et al, 2005; Schimanski et al, 2005; Sun
et al, 2005). Beside the effect on tumour dissemination, CXCR4 as
well as other chemokine receptors have also been implicated in
various aspects of tumour progression such as cancer cell
proliferation and survival as well as in the regulation of the
leukocytic and endothelial milieu within the tumour environment
(Vlahakis et al, 2002; Koizumi et al, 2007).
Among the other chemokine receptors under study in this
context, CXCR3 has been identified in various cancer cells (Jones
et al, 2000; Goldberg-Bittman et al, 2004; Ben-Baruch, 2006; Engl
et al, 2006; Albini and Sporn, 2007) and was recently reported to
play an important role in breast cancer metastasis to the lung
(Mu ¨ller et al, 2001; Kawada et al, 2004) as well as in melanoma and
colon cancer metastasis to the lymph nodes (Walser et al, 2006;
Kawada et al, 2007). However, so far, the relevance of CXCR3
expression levels in colon cancer metastasis to liver and lung,
which remains the major leading cause of death in this
malignancy, has not been investigated.
This study aimed precisely at getting new insights into the role
played by CXCR3/ligands interactions in the metastatic develop-
ment of CRC cells within both target organs. In vitro, we have
analysed how CXCR3 activation by its cognate ligands on CRC
cells of human and mouse origins could lead to malignancy-related
activities, namely proliferation, survival and migration. Besides, to
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stake into account the heterogeneity of target organs, micro-
environmental factors and immune mechanisms, we have developed
models of lung and liver metastatic colon cancer using human and
mouse tumour cells into immunodeficient and immunocompetent
mice. Using a pharmacologic CXCR3 antagonist, we have assessed
the contribution of CXCR3 receptors to the formation and the
growth of liver and lung metastases and evaluated the therapeutic
potential of systemic CXCR3 blockade as an anti-metastatic
strategy for this malignancy.
MATERIALS AND METHODS
Tumour cell lines and experimental animals
Human HT29 and mouse C26 colon carcinoma cells were
maintained in McCoy’s 5A medium and murine B16F10 melanoma
in MEM medium, both supplemented with 10% heat-inactivated
foetal bovine serum (FBS). Female SCID, Nude and BALB/c mice,
6–8-weeks old, were purchased from Harlan (Gannat, France). All
of the procedures involving laboratory animals and their care were
conducted in accordance with institutional guidelines under
veterinary supervision.
Western blot analysis
Colorectal carcinoma and B16F10 cells were grown in serum-
containing medium for 96h. Cell lysates were subjected to SDS–
PAGE and western blotting with rabbit polyclonal antibodies
against CXCR3 (Santa Cruz Biotechnology, Tebu, Le Perray-en-
Yvelines, France). Detection was done by secondary HRP-
conjugated goat antibodies against rabbit IgG (Dako, Trappes,
France). The blot was reprobed with anti-Hsp-60 antibodies (Santa
Cruz Biotechnology, Santa Cruz, CA, USA) to control for equal
loading. Bands were visualised by chemiluminescence-enhanced
reaction (Amersham, Les Ulis, France).
TaqMan real-time PCR experiments
Total RNA from human colorectal cancer and healthy colon, from
healthy mouse and metastatic tissues as well as colon carcinoma
cell lines was extracted using RNeasy kit (Qiagen, Courtaboeuf,
France) and transcribed into cDNA using the Superscript III
enzyme (Invitrogen, Cergy Pontoise, France). Real-time PCR was
performed in an ABI PRISM 7000 and carried out using TaqMan
gene expression assays (Applied Biosystem, Courtaboeuf, France).
Cycle parameters were 501C for 2min, 951C for 10min followed by
40 cycles of 951C for 15s and 601C for 1min. Relative levels in
mRNA expression were determined using DCT values obtained by
subtracting CT control (human actin, mouse rasIP) from CT target
gene (human and mouse CXCR3, CXCL9, CXCL10 or CXCL11),
measured in the same RNA preparation.
In vitro chemotaxis assay
Chemotactic responses of colon cancer cells were evaluated by
using 24-well cell migration chambers with 8mm pore inserts
(Becton Dickinson, San Jose, CA, USA) coated with 6.5mgml
 1
fibronectin (Sigma, St Louis, MO, USA) or with 50mgml
 1 collagen
(Becton Dickinson) for the C26 cells or the HT29 cells,
respectively. Colon cancer cells treated or not with 1mmoll
 1
AMG487 or dimethyl sulfoxide (DMSO) vehicle were placed in the
upper well (5 10
4 cells) and various concentrations of human or
mouse rCXCL9, rCXCL10 and rCXCL11 (all from R&D systems)
were added to the lower wells. After incubation of the plates for
18h (C26 cells) or for 40h (HT29 cells) at 371Ci n5 %C O 2
atmosphere, non-migrated cells were removed from the upper well
and the migrated cells collected on the lower side of the insert were
stained using crystal violet dye and enumerated. Migration index
was calculated as the ratio of the number of migrated cells in
chemoattractant-containing wells divided by the number of cells
that migrated to base medium alone.
In vitro proliferation assay
Colon cancer cells were seeded at a density of 10
4 cellscm
 2 and
incubated either in serum-enriched medium or in base medium
(containing 0.1% bovine serum albumin, BSA) supplemented or
not with various concentrations of rCXCL9, rCXCL10 and
rCXCL11 (all from R&D systems) for the indicated periods of
time before being either trypsin-detached, collected and enumer-
ated or re-fed with fresh medium for 3 days, harvested and
enumerated. The morphology of the CRC cells was observed
through an inverted optical microscope (Leica, Wetzlar, Germany)
at  20 magnification, and photographs were taken at day 7.
Caspase activity
CRC cells were grown as indicated in the proliferation assay.
A positive control of apoptosis was included by treating the cells
for 6h with 1mM staurosporine in serum-enriched medium. Cells
were then lysed and sonicated in 50mM Hepes pH 7.5, 150mM
NaCl, 20mM EDTA, 1mM PMSF, 10mgml
 1 leupeptin, 2mgml
 1
aprotinin and 0.2% NP-40. Equal amount of lysates were mixed in
substrate buffer (50mM Hepes, 100mM NaCl, 1mM EDTA, 10%
sucrose, 0.5% CHAPS, 5mM dithiothreitol) with Ac-DEVD-AMC
substrate (ALEXIS Biochemicals, Illkirch, France) and caspase-3/7
substrate in a microtiter plate. Production of fluorigenic substrate
was measured continuously at 371C in a spectrophotometer Ascent
Fluoroskan (Thermo Fischer Scientific, Cergy Pontoise, France)
and the caspase activity (expressed as Umg
 1 of protein) was
defined as the amount of enzyme cleaving 1nmol of substrate/min.
AMG487 formulation
AMG487 was kindly provided by Amgen (South San Francisco, CA,
USA). The in vitro formulation of AMG487 was prepared as a
10mmoll
 1 stock with DMSO and the antagonist was used at the
final concentration of 1mmoll
 1 for the indicated periods of time
in the in vitro assays. For the preventive treatment with AMG487,
tumour cells growing in culture were washed and re-fed with fresh
growth medium containing 1mmoll
 1 AMG487 or DMSO vehicle.
After 18h at 371C, the tumour cells were washed and processed as
usual for injection into mice. The in vivo formulation of AMG487
was prepared in 20% of hydroxypropyl-b-cyclodextrin (Sigma) as
described earlier (Walser et al, 2006; Wijtmans et al, 2008) and
used to s.c. treat mice twice daily at 5mgkg
 1.
Mouse models of pulmonary and liver metastasis
For the induction of pulmonary metastases, HT29 cells (2 10
6)o r
C26 cells (3 10
4) were delivered by intravenous tail injection into
SCID or Balb/c mice, respectively (Vitale et al, 2007). For the
polymetastatic liver model, 2 10
6 HT29 cells or 5 10
4 C26 cells
were injected intravenously into the portal vein of Nude or Balb/c
mice, respectively. The curative treatment of the mice-bearing
metastases was achieved by treating the animals twice daily on
days þ5t oþ12 (syngeneic C26 model) or on days þ5t oþ23
(immunodeficient HT29 model) with subcutaneous injections of
5mgkg
 1 of AMG487 or vehicle. The preventive treatment to
antagonise CXCR3 was performed by incubating the colon cancer
cells with 1mmoll
 1 of AMG487 or vehicle for 18h in vitro before
their injection into mice and by treating concomitantly the animals
twice daily on days  1 and 0 with subcutaneous injections of
5mgkg
 1 of AMG487 or vehicle. At sacrifice, complete post-
mortem examinations were performed by a veterinary pathologist.
Lungs were inflated and injected through tracheal cannulation
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seither with 10% neutral-buffered formalin before being processed
for routine histology or with 7% India Ink dye that reveals white
tumour nodules against a black lung background. The extent of
tumour development in the lungs was assessed by recording the
number and measuring the tumour nodules visible on the pleural
surface. In the hepatic model, total liver weight was recorded and
compared between the treated and the control groups of mice
before formalin-fixation for morphologic evaluation and immuno-
histochemistry.
Histology/immunohistochemistry
Formalin-fixed, paraffin-embedded sections of colon cancer
metastatic tissues were stained with haematoxylin/eosin and alcian
blue for morphologic evaluation. Immunostaining of CXCR3 was
performed with anti-human CXCR3 mAb (BD Pharmingen, Le
Pont de Claix, France) by the avidin–biotin complex immuno-
peroxidase method following microwave antigen retrieval. The
primary antibody was replaced with phosphate-buffered saline in
adjacent tissue sections as negative control. Expression of CXCR3
in human tonsil was used as positive control.
Statistical analysis
Results are expressed as mean±s.e.m. and analysed using the
unpaired Student’s t-test or ANOVA test with Tukey–Kramer post
test.
RESULTS
CXCR3 expression in colorectal carcinoma
To determine whether CXCR3 is expressed in colon carcinoma
(CRC), we analysed by quantitative RT–PCR (real-time quantita-
tive reverse transcription polymerase chain reaction) the expres-
sion levels of CXCR3 on surgical re-section pieces of human colon
carcinoma and on corresponding healthy colon tissues. Our
analysis indicated that the CXCR3 receptor is expressed in healthy
human colon tissues (n¼14) and moderately over-expressed in
the biopsies of CRC (n¼30) (Figure 1A). To address the question
whether CXCR3 receptors regulate malignancy-related properties
of CRC cells such as invasion and metastasis formation, we have
extended our analyses to CRC cell lines of human (HT29 cells) and
murine (C26 cells) origins that enable the development of liver and
lung metastases when injected into immunodeficient and im-
munocompetent mice, respectively. Protein expression of CXCR3
was detected by western blotting in human HT29 cells as well as in
murine C26 cells (Figure 1B); B16F10 melanoma cells providing a
positive control of CXCR3 protein expression as described earlier
(Kawada et al, 2004). We next evaluated the ability of the mouse
healthy lung and liver to produce the corresponding CXCR3
ligands. Analyses by quantitative RT–PCR done on mouse CXCL9,
CXCL10 and CXCL11 indicated that all three chemokines were
expressed by healthy lung and liver tissues (Figure 1C).
CXCR3 mediates the migration of colorectal carcinoma
cells induced by the CXCR3 ligands
The expression of CXCR3 receptors by human and murine colon
carcinoma cells has led us to determine the ability of the
corresponding ligands (mouse CXCL9, CXCL10 and CXCL11) to
induce their migration in vitro. To this end, C26 cells as well as
HT29 cells were harvested, placed into cell migration chambers
and allowed to migrate towards various concentrations of CXCL9,
CXCL10, CXCL11 or base medium alone. Figure 2A shows that C26
cells migrated to each of the chemokines in a dose-dependent
manner compared with base medium alone. The maximum
migratory response was observed in response to CXCL10
(30–100ngml
 1) but also occurred at 10–100ngml
 1 with CXCL9
and at 1–30ngml
 1 with CXCL11. These results suggest that
CXCR3 activation by its cognate chemokines can induce invasion-
related properties in C26 cells.
Next, we analysed the ability of AMG487 to affect the
chemokine-induced migration of the cancer cells by performing
the migration assay in the presence of 1mmoll
 1 of AMG487 or
vehicle and by testing the capacity of the cells to respond to the
most effective dose of each chemokine. As shown in Figure 2B, the
CXCR3 antagonist significantly inhibited the migratory responses
of the C26 cells to each of the three ligands, thus confirming the
specificity of the chemotactic response induced by the chemokines.
We next examined whether the human HT29 colon cancer cells
exhibited similar abilities as the mouse C26 cells to migrate
through their CXCR3 receptors. As for the murine cells, the
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Figure 1 Expression of CXCR3 in human and mouse colon carcinoma.
(A) Quantitative RT–PCR analysis of CXCR3 in surgical resection pieces
of human colon carcinoma (n¼30) compared with healthy colon tissues
(n¼14). The relative levels of CXCR3 expression were calculated using
standard curves and expressed as 1/DCT. DCT values were calculated by
subtracting CT of normalising gene from CT of target gene, measured in the
same RNA preparation. (B) Western blot analysis of CXCR3 expression in
murine C26 and human HT29 colon carcinoma cells, melanoma B16F10
cells being used as a positive control. (C) Expression of CXCR3 ligands in
mouse healthy lung (hatched bars) and healthy liver (black bars). Relative
levels of expression are determined by quantitative RT–PCR analysis using
mouse rasIp as normalising gene. (n¼6 mice/group). *Po0.01,
**Po0.001.
CXCR3 in liver and lung metastases of colon cancer
B Cambien et al
1757
British Journal of Cancer (2009) 100(11), 1755–1764 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
schemotactic responses towards various concentrations of chemo-
kines were tested and confirmed the migratory ability of the
human tumour cells in response to two of the three ligands
(CXCL9, CXCL10 but not CXCL11) (Figure 2C). The maximum
chemotaxis occurred in response to 10ngml
 1 CXCL10 and to
30ngml
 1 CXCL9. Additionally, in line with our previous results
in the C26 cells, the chemokine-induced migration of the HT29
cells was blocked by the molecular CXCR3 antagonist. These data
suggest that CXCR3 activation by its cognate ligands appears as a
common feature of the CRC cells from distinct origins and that it
could mediate the invasion-related properties of colon cancer cells.
CXCR3 mediates the chemokine-induced survival of the
C26 tumour cells
To establish whether CXCL9, CXCL10, CXCL11 can modulate the
growth/survival ability of the colon cancer cell line in culture, we
examined and quantified cell growth after plating C26 and HT29
cells for 5 days at low density in base medium alone (serum
starvation) or supplemented with various concentrations of
CXCL9, CXCL10 or CXCL11. For murine cells, we observed that
only CXCL10 could significantly increase cell survival within 5
days of serum starvation (Figure 3A). In contrast, a significant
increase in viability compared with the base medium alone was
observed when the cells were first treated with CXCL9, CXCL10 or
CXCL11 during the 5-day starvation period before being re-fed
with fresh medium for 3 days (Figures 3B and 4). As observed
under microscope, the C26 cells grown in serum-enriched medium
showed complete attachment to the surface (Figure 4, FBS
condition). In contrast, tumour cells that underwent serum
starvation for 5 days before being re-fed fresh medium (BSA
condition), looked barely attached to the surface and were mostly
found in suspension as reflected in the enumerated adherent cells
(Figure 3C). Simply supplementing the BSA condition either with
CXCL9, CXCL10 or CXCL11 allowed the cells to reverse this non-
attached phenotype and to survive in culture. Clearly,
however, this gain in proliferation/survival was abrogated by
AMG487 treatment, thus indicating the involvement of CXCR3 in
the chemokine-induced proliferation of the C26 cells (Figures 3C
and 4).
Similar growth ability afforded by chemokine treatments on
serum starvation was found for the human HT29 cells as shown in
Figure 3D, the benefit being already detectable after a 5-day
treatment of the cells. Here again, CXCR3 antagonism through
AMG487 abrogated this cell response (Figure 3D). These findings
suggest that both human and murine colon cancer cells share the
ability to respond to CXCR3 activation in terms of proliferation.
Because serum starvation may represent proapoptotic condi-
tions for the cells as depicted in Figure 4, we next evaluated
whether tumour cells could undergo caspase-dependent cell death
in base medium (BSA condition) but be protected by chemokine
treatments. As a positive control of apoptosis, CRC cells were
subjected to a proapoptotic treatment with staurosporine and
rapidly underwent apoptosis as revealed by measurement of
caspases-3/7 activation (data not shown). However, we failed to
detect any change in caspase activation when CRC cells were
subjected to serum deprivation. These data suggest that serum-
starvation-triggered cell death is associated with a caspase-
independent mechanism in HT29 and C26 colon cancer cells but
that a protection from death is afforded by CXCR3 activation in
these cells.
Systemic CXCR3 antagonism reduces pre-established lung
metastases but not liver metastases from colon cancer
On the basis of inhibitory effect of AMG487 on the proliferative
ability of both HT29 and C26 cells in culture, we seeked to evaluate
the potential-blocking effect of this coumpound on pre-established
lung and liver metastases in immunodeficient and immunocom-
petent mice. At day 0, the CXCR3-positive HT29 cells or C26 cells
were injected either into the tail vein or into the portal vein of mice
to generate lung or liver metastases, respectively. Mice were then
treated twice daily on days þ5t oþ23 (HT29 model) or on days
þ5t oþ12 (C26 model) with s.c. injections of 5mgkg
 1 of
AMG487 or vehicle, dose described earlier to be therapeutic
(Walser et al, 2006). At sacrifice, the extent of tumour development
in the lung was assessed by measuring and recording the number
of tumour nodules visible on the pleural surface. All the mice from
both the vehicle- and the AMG487-treated groups developed
pulmonary metastases (Figure 5A and D). However, the AMG487-
treated mice exhibited fewer pulmonary nodules than the control
mice in both the models: a 62% reduction in the human model (3.3
vs 8.8, P¼0.005) and 42% less nodules in the mouse model (78 vs
134, P¼0.003). The inhibitory effect of AMG487 treatment was
also detectable in the cumulative tumour volume with a reduction
by 58% in the lungs of the HT29-injected immunodeficient mice
(4.6 vs 10.9mm
3, P¼0.01) (Figure 5B) and by 51% (93 vs 189mm
3,
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Figure 2 Chemokine-induced migration of colon carcinoma cells. C26
cells (A and B) or HT29 cells (C) were placed in the upper well of a
migration chamber and assayed for chemotaxis in response to the indicated
concentrations of recombinant CXCL9, CXCL10, CXCL11, to base
medium alone (basal) or to serum-enriched medium (FBS). (B) Effect of
CXCR3 antagonism by AMG487 on the chemotactic response of C26 cells
to CXCL9 (10ngml
 1), to CXCL10 (30ngml
 1) or to CXCL11
(30ngml
 1). (C) Impact of CXCR3 blockade on the migratory response
of HT29 cells to CXCL9 (10ngml
 1), to CXCL10 (20ngml
 1)o rt o
CXCL11 (10ngml
 1). Results represent the mean±s.e.m. of six
determinations. *Po0.05, **Po0.001.
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Figure 3 Effect of CXCR3 activation on the proliferation of colon carcinoma cells. (A) C26 cells proliferation on serum starvation was assessed in
response to a 5-day treatment with the indicated concentrations of either CXCL9 (black bars), or CXCL10 (white bars), or CXCL11 (gray bars), or with
base medium alone (hatched bars) or with serum-enriched medium (dotted bars). (B) C26 tumour cells were grown for 5 days as described above (panel
A) before being re-fed fresh medium for 3 days and enumerated. (C and D) Effect of CXCR3 antagonism by AMG487 on the growth response of C26 cells
(C) induced by CXCL9 (30ngml
 1), by CXCL10 (10ngml
 1) or by CXCL11 (10ngml
 1) or on the proliferation of HT29 cells (D) in response to CXCL9
(3ngml
 1), to CXCL10 (3ngml
 1) or to CXCL11 (30ngml
 1). Results are expressed as mean ± s.e.m. from six independent determinations. *Po0.05,
**Po0.001, ***Po0.0001.
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sPo0.001) in the lungs of the C26-injected syngeneic mice
(Figure 5E). These data indicate that CXCR3 is involved in the
metastatic development of CRC cells within lung tissues and that
blockade of the CXCR3/ligands axis significantly reduces the
progression of pre-established pulmonary nodules. Given that liver
is a major target organ in the CRC malignancy, we next assessed
the anti-tumour potential of AMG487 on liver metastases-bearing
mice. Strikingly, however, systemic antagonism performed with
AMG487, at the dose shown earlier to be effective in the lungs, did
not lead to any significant decrease in the tumour development in
the liver, both in the HT29 and in the C26 tumour models (Figure
5C and F), thus suggesting that the metastatic progression of CRC
cells within the liver might rely on distinct mechanisms than in the
lungs.
CXCR3 antagonism affects the metastatic spread of C26
cells to the lungs but not to the liver
On the basis of chemotactic-promoting effect of CXCR3/ligands
interactions on CRC cells, we next investigated the contribution of
this axis in the implantation of colon carcinoma within lungs and
liver by developing a preventive blockade of CXCR3 before tumour
cell inoculation into mice. As CXCR3 antagonism may not only
impact on tumour cells but also on CXCR3-dependent immune
mechanisms as well, working with the immunocompetent meta-
static models appeared more appropriate to assess the anti-
metastatic potential of this strategy. Therefore, the CXCR3-positive
C26 colon carcinoma cells were pre-treated with 1mmoll
 1 of
AMG487 or vehicle for 18h in vitro before being injected into
syngeneic BALB/c mice to generate either pulmonary or liver
metastases. To reinforce the blockade of CXCR3 at the time of CRC
cell implantation within the target organs, mice were also treated
twice daily before tumour cell inoculation (on days  1 and 0) with
s.c. injections of 5mgkg
 1 of AMG487 or vehicle. Twelve days
after the inoculation of the C26 tumour cells, the extent of tumour
development in both target organs was assessed as described
above. As shown in Figure 6, 100% of the mice from both groups
developed numerous macroscopic pulmonary foci. However, there
was a significant reduction in the overall tumour development in
the lungs of the AMG487-treated mice compared with the control
group as reflected in both the number of foci (37% reduction; 102
vs 164, P¼0.003) and in the cumulative tumour volume (39%
reduction 112 vs 185mm
3, P¼0.0002) (Figure 6A and B).
We also evaluated the effect of AMG487 on the implantation of
hepatic metastases by C26 cells. As in the lung metastasis model,
100% of the mice from both groups developed numerous
macroscopic liver nodules (Figure 6C). In contrast, however, there
was no significant difference in the overall tumour load in the
livers between both groups, as assessed by liver weight (3.03 vs
2.89g, P¼0.7).
Comparative analysis of CXCR3/ ligands expression
between liver and lung
The organ-specific inhibition of metastatic colon cancer carcinoma
by CXCR3 antagonism has led us to examine CXCR3 expression
within lung and liver experimental metastases. To differentiate
between CXCR3 expression by the tumour tissues and that by the
surrounding healthy organ, we have examined the human HT29
metastases implanted within mouse tissues using antibodies
specifically directed against the human protein through immuno-
histochemistry. As shown in Figure 7A, we observed a marked
difference in the human CXCR3 staining between sections of lung
and liver metastases both in the percent of CXCR3-positive colon
cancer cells and in the expression intensity within the CRC cells
cytoplasm. These data indicating a stronger expression of CXCR3
in lung metastases compared with liver foci was further confirmed
by quantitative RT–PCR (Figure 7B). Using human probes, we
found that lung metastases exhibited a 3.5 increase in the level of
human CXCR3 mRNA expression compared with liver nodules.
Besides tumour cells, mouse lung tissues also expressed higher
mRNA expression levels for the mouse receptor. Strikingly,
however, more marked differences were measured in the amount
of messengers encoding CXCR3 ligands between both tumours.
Except for human CXCL9, in which mRNA levels in the lung
tumours were not detectable, we observed significantly higher
expressions of human CXCL10 (33-fold increase) and CXCL11 (28-
fold increase) by the lung CRC metastases, which suggest a
possible mechanism for the lung CRC metastases to promote their
development.
DISCUSSION
Preventing and eradicating metastases in the target organs implies
to better understand the mechanisms of organ-specific metastasis.
Recently, chemokines receptors have emerged as important
mediators in determining the metastatic potential and site-specific
spread of cancer cells, their cognate ligands being expressed by the
target organs. In colon carcinoma, we have observed that CXCR3
receptors are moderately over-expressed in biopsies of CRC
patients compared with healthy colon, confirming the recent
report of Kawada et al (2007). Although this group recently
reported the crucial role played by CXCR3 in the metastatic
process of CRC to lymph nodes, the relevance of CXCR3
expression in colon cancer metastasis to liver and lung, which
remain the major cause of mortality in this pathology, has not been
addressed. To this aim, we have extended our analyses to CRC cell
lines of human (HT29 cells) and murine (C26 cells) origins that
both express CXCR3 and enable the development of experimental
liver and lung metastases when injected into mice. Additionally, we
FBS BSA
BSA + CXCL9 BSA + CXCL10 BSA + CXCL11
DMSO
AMG487
Figure 4 Representative optical photographs of C26 cells morphology in
proliferation/survival assays. The C26 cells grown in serum-enriched
medium showed complete attachment to the surface (FBS) but underwent
detachment followed by cell death on serum starvation (BSA). Supple-
mentation of the serum-deprived medium with either CXCL9, or CXCL10
or CXCL11 allowed the majority of the tumour cells to reverse this non-
attached phenotype and to be protected from death. This benefit in
survival was abrogated when tumour cells were co-incubated in the
presence of AMG487. The morphology of the CRC cells was observed at
day 7 through an inverted optical microscope (Leica, Germany) at  20
magnification. Similar observations were done with the HT29 tumour cell
line within 5 days of culture.
CXCR3 in liver and lung metastases of colon cancer
B Cambien et al
1760
British Journal of Cancer (2009) 100(11), 1755–1764 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
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healthy lung and liver to produce the corresponding CXCR3
ligands: CXCL9, CXCL10 and CXCL11. To reach an understanding
of the role played by CXCR3 in colon cancer metastasis to liver and
lung, we first analysed the direct function of CXCR3 on the tumour
cells in vitro before assessing its involvement in the implantation
and the progession of colon carcinoma within the two main target
organs in vivo.
The expression of CXCR3 receptors by CRC human tissues and
by the human HT29 cells and the murine C26 tumour cells has led
us to determine the ability of the corresponding ligands, CXCL9,
CXCL10 and CXCL11 to affect the growth and chemotactic
responses of HT29 and C26 cells in vitro. Here, we show that
activation of CXCR3 by its ligands results in both human and
mouse tumour cell proliferation, survival and chemotaxis. Taken
together, our in vitro results directly support the hypothesis that
all three CXCR3 ligands display metastasis-promoting activities in
CRC cells. Moreover, both motility and growth responses of the
colon cancer cells are considerably reduced by AMG487, a small
molecular antagonist of CXCR3, thus indicating that CXCR3 may
play a major role in the spread and progression of colon cancer
metastases in vivo.
As a next step, we investigated the relevance of CXCR3
expression levels for colon cancer metastasis to the two main
target organs, liver and lung, using two metastatic mouse models.
Given that the pharmacologic antagonist of CXCR3 affects the
proliferation and the migratory behaviour of both human and
murine CRC cell lines in vitro, we tested whether a systemic
treatment with AMG487 could affect local growth of pre-
established metastases. Interestingly, the curative systemic antag-
onism of CXCR3 markedly reduced both the number of nodules
and the cumulative tumour volume within lungs of both HT29
and C26-inoculated mice whereas liver tumours remained
unaffected. Thus, CXCR3 appears to contribute to the progression
of colon cancer metastases in the lung. In contrast to other
published studies that tested the involvement of CXCR3 in cancer
progression by performing CXCR3 inhibition at the time of cancer
cells implantation within the target organ, our results provide the
first evidence of the therapeutic potential of CXCR3-blocking
strategies on pre-existing lung metastases. On the basis of the
chemotactic effect of CXCR3 ligands on the CRC tumour cells
in vitro, we further tested the hypothesis that metastases
implantation in the liver and in the lung is facilitated by CXCR3
expression on the tumour cell surface. We, therefore, performed
experimental metastatic models that selectively address the impact
of CXCR3 blockade on the extravasation step of the CRC cells by
inoculating the cancer cells into mice through intravenous
injections in both the hepatic and the pulmonary models. CRC
cells were pre-treated with AMG487 or vehicle before being
injected into mice and the preventive action of AMG487 was
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Figure 5 Curative effect of AMG487 on the development of pre-established colon cancer metastases. Mice were injected with HT29 cells (A–C)o r
with C26 cells (D–F) either into the tail vein (A, B, D and E) or into the portal vein (C and F) before receiving subcutaneous injections of AMG487 or
vehicle as described in ‘Materials and Methods’ section. On sacrifice, the extent of tumour development was assessed by recording the number of pulmonary
metastases (A and D), by measuring the cumulative tumour volume in the lung (B and E) and by weighing the livers in the hepatic models (C and F). The
Student’s t-test was used for statistical analysis: ns, not significant. (n¼7–12 mice per group).
CXCR3 in liver and lung metastases of colon cancer
B Cambien et al
1761
British Journal of Cancer (2009) 100(11), 1755–1764 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sstrengthened by performing a concomitant systemic administra-
tion of the antagonist at the time of tumour cells inoculation into
mice. Despite the fact that all the treated and control mice
exhibited lung metastases at necropsy, we observed a significant
reduction in lung metastasis formation in response to the
preventive treatment with CXCR3 antagonist. These data indicate
that if CXCR3 blockade does not fully prevent CRC cells
implantation into the lung, this antagonism is, however, very
efficient in limiting this process. However, in contrast to the effects
on pulmonary metastasis, the extent of liver metastasis was not
affected by the preventive CXCR3 antagonism, pointing to the fact
that CXCR3 may mediate organ-specific implantation of colon
carcinoma in this model.
Along with our findings, the results by Kawada et al (2007) show
that targeting CXCR3 is also protective against CRC metastasis to
lymph nodes, which underscore the critical role played by this
receptor in promoting colon cancer metastasis to various distant
organs. Additionally, the organ-specific effect of CXCR3 blockade
has also been observed in melanoma (Kawada et al, 2004). In that
study, CXCR3 was also responsible for lymph nodes metastasis of
murine melanoma without affecting that of the lung indicating the
role played by CXCR3 in the organ-specific metastasis of distinct
cancer cells. Besides colon carcinoma and melanoma, mammary
tumour cells were also reported to express CXCR3 that facilitates
the development of lung metastasis (Walser et al, 2006); therefore,
suggesting that CXCR3 may be an important mediator for tumour
cells dissemination to the lung.
To gain further insight into the organ-specific inhibition of
metastatic CRC through CXCR3 antagonism, we analysed CXCR3
expression within lung and liver tumour nodules. Both our
immunohistochemistry and quantitative RT–PCR studies pointed
to a higher expression level of the receptor within pulmonary
metastases than in the hepatic foci. In addition, higher levels of
CXCR3 ligands expression were also measured in lung tumours
compared with liver tissues. It is, therefore, tempting to speculate
that the CXCR3/chemokines axis may facilitate implantation,
growth/survival and expansion of the cancer cells within lung
tissues. Apart from the cancer cells, CXCR3 is known to be
heterogeneously expressed within tissues (Garcı ´a-Lo ´pez et al,
2001). In line with this, we found increased levels of CXCR3
expression within mouse healthy lung tissues compared with
healthy liver. It is thus conceivable that CXCR3 blockade through
systemic antagonism in the environment of lung metastases
contributed to interfere with tumour development. Further
elucidating this precise aspect that was beyond the scope of our
study, will require approaches performing the specific silencing of
CXCR3 on the tumour colon cancer cells.
Despite accumulating evidence of malignancy-related functions
of CXCR3 in various cancers, the functions that chemokines and
their receptors establish between the tumour cells and their
microenvironment are complex, ranging from support to inhibi-
tion of the tumourigenesis process (Ben-Baruch, 2006). In
particular, the ability of chemokines to attract into tumours
leukocytes with potential anti-tumour activities is of importance.
Beside its expression on colon cancer cells, CXCR3 is indeed
expressed on T lymphocytes, dendritic cells, monocytes, natural
killer cells (Qin et al, 1998; Katschke et al, 2001; Penna et al, 2002;
Rabin et al, 2003) and was reported as an important receptor for
the immune response to be optimally executed (Loetscher et al,
1996). Likewise, several studies have now clearly showed
the anti-tumour activities of the CXCR3 ligands in various
syngeneic tumour models (Luster and Leder, 1993; Sgadari et al,
1996; Addison et al, 2000; Dorsey et al, 2002; Feldman et al, 2002;
Giese et al, 2002; Wang et al, 2003; Saudemont et al, 2005; Walser
et al, 2007; Zipin-Roitman et al, 2007). Consistent with this, we
were expecting that neutralising all interactions between
CXCR3 and its ligands by systemic CXCR3 antagonism could
promote metastasis. However, the extent of tumour development
was never significantly enhanced in the AMG487-treated mice
compared with the corresponding control group, indicating
that the CXCR3 antagonism did not affect the local tumour
growth. Although no adverse effect on tumour development was
observed in our experiments as well as when AMG487 was
systemically administered for 28 days in metastatic breast cancer
(Walser et al, 2006), further effort will be required to examine this
possibility, especially considering that CXCR3 blockade may be
useful as a treatment strategy to interfere with metastasis in cancer
patients.
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Figure 6 Inhibition of colon carcinoma metastases by preventive
treatment with the antagonist AMG487. The preventive treatment to
antagonise CXCR3 consisted in treating with AMG487 or vehicle both the
C26 cells in vitro before their inoculation and the mice on days  1 and 0 as
described in ‘Materials and Methods’ section. At day 0, C26 cells were then
injected into the tail vein to generate pulmonary metastases (A and B)o r
into the portal vein for hepatic metastases (C). Twelve days later, the
extent of tumour development was assessed by recording the number of
tumour nodules visible in the lungs (A), by calculating the cumulative
tumour volume (B) and by weighing the livers (C). The Student’s t-test was
used for statistical analysis: ns, not significant. (n¼8–12 mice per group).
CXCR3 in liver and lung metastases of colon cancer
B Cambien et al
1762
British Journal of Cancer (2009) 100(11), 1755–1764 & 2009 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sIn summary, our results show that CXCR3 expression and
activation is associated with tumour-promoting activities on colon
cancer cells in vitro, namely proliferation, survival and migration.
The in vivo data point to a distinct contribution of the CXCR3/
chemokines axis between lung and liver CRC metastases.
Preventive systemic treatment with AMG487, a small molecular
weight antagonist of CXCR3, significantly reduces metastasis of
colon cancer cells to the lung without affecting that to the liver. In
addition, our study shows for the first time that using AMG487 as a
curative treatment on pre-established metastases markedly reduces
tumour development in the lung but not in the liver. Along with
the protective action of CXCR3 antagonism on CRC metastasis to
lymph nodes reported by Kawada et al, our findings provide
evidence that targeting the CXCR3/ ligands axis may be beneficial
in limiting metastatic colon cancer.
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